Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DSP 107

Next Previous
Drug Profile

DSP 107

Alternative Names: DSP-107; KAHR-107

Latest Information Update: 23 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KAHR Medical
  • Developer KAHR Medical; Roche
  • Class Antineoplastics; Immunotherapies; Proteins; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity; Macrophage stimulants; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Acute myeloid leukaemia; Diffuse large B cell lymphoma; Myelodysplastic syndromes

Most Recent Events

  • 07 Nov 2025 Kahr Medical terminates a phase I clinical trial in Myelodysplastic syndromes (Combination therapy, Second-line therapy or greater) due to slow enrolment in USA (IV) (NCT04937166)
  • 02 Jun 2025 Efficacy and adverse event data from a phase I/II trial in Solid tumours released by KAHR Bio
  • 30 May 2025 Efficacy, adverse evenet and pharmacodynamics data from a phase I/II trial in Solid tumours presented at 61st Annual Meeting of the American Society of Clinical Oncology 2025 (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top